Advertisement

Three-dimensionally plotted MBG/PHBHHx composite scaffold for antitubercular drug delivery and tissue regeneration

  • Kun Li
  • Min Zhu
  • Peng Xu
  • Yanhai Xi
  • Zisheng Cheng
  • Yufang ZhuEmail author
  • Xiaojian YeEmail author
Engineering and Nano-engineering Approaches for Medical Devices
Part of the following topical collections:
  1. Engineering and Nano-engineering Approaches for Medical Devices

Abstract

A suitable drug-loaded scaffold that can postoperatively release an antituberculosis drug efficiently in a lesion area and help repair a bone defect is very important in the clinical treatment of bone tuberculosis (TB). In this study, a composite drug-loaded cylindrical scaffold was prepared by using three-dimensional printing technology in combination with the mesoporous confinement range, surface chemical groups, and gradual degradation of poly(3-hydroxybutyrate-co-3-hydroxyhexanoate). This achieves the slow release of a drug for as long as possible. We implanted the drug-loaded compound scaffold into New Zealand rabbits’ femur defect model to study the in vivo drug release performance and osteogenic ability. The in vivo release of isoniazid and rifampicin from the prepared composites could be effectively sustained for 12 weeks in local tissues, whereas these drugs were sustained for just 2 weeks in a control group. The blood drug concentrations were very low and most concentrations were below 5 μg/ml. Therefore, the systemic toxic adverse effect is very low. In addition, the composite exhibits good osteogenic potential in a rabbit bone defect model. The results of this study indicate that this composite has great potential for treating osteoarticular TB.

Keywords

Bone Defect Composite Scaffold Blank Control Group MTES Antitubercular Drug 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgments

This work was financially supported by the Shanghai Nanometer Special Project (No. 11nm0504200), the National High Technology Research and Development Program of the Science and Technology Ministry of China (863 Program, No. 2013AA032203), the National Nature Science Foundation of China (Grant No. 51302170) and Shanghai Nature Science Foundation (13ZR1458600).

References

  1. 1.
    Zumla A, George A, Sharma V, Herbert N. Ilton BMo. WHO’s 2013 global report on tuberculosis: successes, threats, and opportunities. Lancet. 2013;382(9907):1765–7.CrossRefGoogle Scholar
  2. 2.
    Xue MT, Hu HG, Jiang YQ, Liu JC, He HL, Ye XJ. Biodegradable polymer-coated, gelatin hydrogel/bioceramics ternary composites for antitubercular drug delivery and tissue regeneration. J Nanomater. 2012. doi: 10.1155/2012/530978.Google Scholar
  3. 3.
    Haldar S, Ghosh P, Ghosh A. Tuberculous arthritis—the challenges and opportunities: observations from a tertiarycenter. J Rheumatol. 2011;6:62–8.Google Scholar
  4. 4.
    Kailasam S, Wise DL, Gangadharam PRJ. Bioavailability and chemotherapeutic activity of clofazimine against Mycobacterium avium complex infections in beige mice following a single implant of a biodegradable polymer. J Antimicrob Chemother. 1994;33(2):273e9.CrossRefGoogle Scholar
  5. 5.
    Manisha D, Khuller GK. Sustained release of isoniazid from a single injectable dose of poly (dl-lactide-co-glycolide) microparticles as a therapeutic approach towards tuberculosis. Int J Antimicrob Agent. 2001;17:115e22.Google Scholar
  6. 6.
    Vallet-Regí M, Balas F, Arcos D. Mesoporous materials for drug delivery. Angew Chem Int Ed. 2007;46(40):7548e58.CrossRefGoogle Scholar
  7. 7.
    Dutt M, Khuller GK. Liposomes and PLG microparticles as sustained release antitubercular drug carriers—an in vitro-in vivo study. Int J Antimicrob Agent. 2001;18:245.CrossRefGoogle Scholar
  8. 8.
    Hirota K, Hasegawa T, Nakajima T, Inagawa H, Kohchi C, Soma G, Makino K, Terada H. Delivery of rifampicin-PLGA microspheres into alveolar macrophages is promising for treatment of tuberculosis. J Control Releas. 2010;142:339.CrossRefGoogle Scholar
  9. 9.
    Onoshita T, Shimizu Y, Yamaya N, Miyazaki M, Yokoyama M, Fujiwara N, Nakajima T, Makino K. The behavior of PLGA microspheres containing rifampicin in alveolar macrophages. Colloid Surf B. 2010;76:151.CrossRefGoogle Scholar
  10. 10.
    Yan XX, Yu CZ, Zhou XF, Tang JW, Zhao DY. Highly ordered mesoporous bioactive glasses with superior in vitro bone-forming bioactivities. Angew Chem Int Ed. 2004;44:5980–4.CrossRefGoogle Scholar
  11. 11.
    Fan Y, Yang PP, Huang SS, Jiang JH, Lian HZ, Lin J. Luminescent and mesoporous europium-doped bioactive glasses as a drug carrier. J Phys Chem C. 2009;113(18):7826–30.CrossRefGoogle Scholar
  12. 12.
    Lei B, Chen X, Wang Y, Zhao N. Synthesis and in vitro bioactivity of novel mesoporous hollow bioactive glass microspheres. Mater Lett. 2009;63(20):1719–21.CrossRefGoogle Scholar
  13. 13.
    Lopez-Noriega A, Arcos D, Izquierdo-Barba I. Ordered mesoporous bioactive glasses for bone tissue regeneration. Chem Mater. 2006;13:3137–44.CrossRefGoogle Scholar
  14. 14.
    Xia W, Chang J. Well-ordered mesoporous bioactive glasses (MBG): a promising bioactive drug delivery system. J Control Release. 2006;3:522–30.CrossRefGoogle Scholar
  15. 15.
    Xia W, Chang J, Lin JP. The pH-controlled dual-drug release from mesoporous bioactive glass/polypeptide graft copolymer nanomicelle composites. Eur J Pharm Biopharm. 2008;2:546–52.CrossRefGoogle Scholar
  16. 16.
    Wu WG, Zheng QX, Guo XD, Sun JH, Liu YD. A programmed release multi-drug implant fabricated by three-dimensional printing technology for bone tuberculosis therapy. Biomed Mater. 2009;4:065005.CrossRefGoogle Scholar
  17. 17.
    Chen MW, Le DQ, Hein S, Nygaard JV, Kassem M, Kjems J, Besenbacher F, Bünger C. Fabrication and characterization of a rapid prototyped tissue engineering scaffold with embedded multicomponent matrix for controlled drug release. Int J Nanomed. 2012;7:4285–97.CrossRefGoogle Scholar
  18. 18.
    Wu CT, Luo Y, Cuniberti G, Xiao Y, Gelinsky M. Three-dimensional printing of hierarchical and tough mesoporous bioactive glass scaffolds with a controllable pore architecture, excellent mechanical strength and mineralization ability. Acta Biomater. 2011;7:2644–50.CrossRefGoogle Scholar
  19. 19.
    Yun HS, Kim SE, Hyun YT. Three-dimensional mesoporous-giantporous inorganic/organic composite scaffolds for tissue engineering. Chem Mater. 2007;26:6363–6.CrossRefGoogle Scholar
  20. 20.
    Shangguan YY, Wang YW, Wu Q, Chen GQ. The mechanical properties and in vitro biodegradation and biocompatibility of UV-treated poly(3-hydroxybutyrate-co-3-hydroxyhexanoate). Biomaterials. 2006;27(11):2349–57.CrossRefGoogle Scholar
  21. 21.
    Wang YW, Wu Q, Chen J, Chen GQ. Evaluation of three-dimensional scaffolds made of blends of hydroxyapatite and poly(3-hydroxybutyrate-co-3-hydroxyhexanoate) for bone reconstruction. Biomaterials. 2005;26(8):899–904.CrossRefGoogle Scholar
  22. 22.
    Dong CL, Webb WR, Peng Q, Tang JZ, Forsyth NR, Chen GQ, EI Hai AJ. Sustained PDGF-BB release from PHBHHx loaded nanoparticles in 3D hydrogel/stem cell model. J Biomed Mater Res A. 2014. doi: 10.1002/jbm.a.35149.Google Scholar
  23. 23.
    Song SH, Jun SH, Park KU, Yoon Y, Lee JH, Kim JQ, Song J. Simultaneous determination of first-line anti-tuberculosis drugs and their major metabolic ratios by liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom. 2007;21(7):1331–8.CrossRefGoogle Scholar
  24. 24.
    Han M, Jun SH, Lee JH, Park KU, Song J, Song SH. Method for simultaneous analysis of nine second-line anti-tuberculosis drugs using UPLC-MS/MS. J Antimicrob Chemother. 2013;68(9):2066–73.CrossRefGoogle Scholar
  25. 25.
    Kim J, McBride S, Tellis B, Alvarez-Urena P, Song YH, Dean DD, Sylvia VL, Elgendy H, Ong J, Hollinger JO. Rapid-prototyped PLGA/beta-TCP/hydroxyapatite nanocomposite scaffolds in a rabbit femoral defect model. Biofabrication. 2012;4(2):025003.CrossRefGoogle Scholar
  26. 26.
    Taira H, Moreno J, Ripalda P, Forriol F. Radiological and histological analysis of cortical allografts: an experimental study in sheep femora. Arch Orthop Trauma Surg. 2004;124(5):320–5.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  1. 1.Department of OrthopedicsChangzheng Hospital of Second Military Medical UniversityShanghaiPeople’s Republic of China
  2. 2.School of Materials Science and EngineeringUniversity of Shanghai for Science and TechnologyShanghaiPeople’s Republic of China

Personalised recommendations